View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports

Moody's Ratings affirms CoStar's Baa3 rating; stable outlook

Moody's Ratings ("Moody's") today affirmed CoStar Group, Inc.'s ("CoStar") Baa3 senior unsecured rating. The outlook remains stable. Governance, CoStar's prudent financial policy in particular, is a key driver of today's action. Moody's believes that the company's financial metrics will remain con...

Costar Group Inc: 2 directors

Two Directors at Costar Group Inc sold/sold after exercising options 126,536 shares at between 92.610USD and 92.670USD. The significance rating of the trade was 59/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all t...

Adtalem Global Education Inc.: Update to credit analysis

Our credit view of this issuer reflects its good competitive position in for-profit higher education sector and its modest financial leverage, offset by ongoing regulatory and legal risks

Moody's announces completion of a periodic review of ratings of Adtale...

Moody's Investors Service (Moody's) has completed a periodic review of the ratings of Adtalem Global Education Inc. and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 28 February 2024 in which Moody's reassessed the appropriateness of...

Gilead Sciences Inc: 1 director

A director at Gilead Sciences Inc sold 10,230 shares at 72.823USD and the significance rating of the trade was 70/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years cle...

Moody's says Gilead's acquisition of CymaBay will enhance liver produc...

Moody's Investors Service commented that Gilead Sciences, Inc.'s announcement that it would acquire publicly-traded CymaBay Therapeutics, Inc. for approximately $4.3 billion will enhance Gilead's expertise in liver disease and provides a solid growth opportunity, a credit positive. At the same time,...

Gilead Sciences, Inc.: Acquisition of CymaBay will enhance liver produ...

CymaBay provides GIlead with a solid growth opportunity in selaldelpar with a minimal impact on key credit metrics.

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

Breakouts Proliferate; Bullish Outlook Intact The S&P 500, Nasdaq 100, and DJI are breaking out to new all-time highs following 3-week consolidations, while the small-cap Russell 2000 (IWM), mid-cap S&P 400 (IJH), Vanguard Extended Market ETF (VXF), and countless other Sectors/industries are breaking out from 3-week bullish falling wedge/flag patterns. This is classic bull market behavior. Considering market dynamics remain healthy, this is all evidence that supports our ongoing bullish outlook...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

Moody's announces completion of a periodic review of ratings of Gilead...

Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of Gilead Sciences, Inc. and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 4 January 2024 in which Moody's reassessed the appropriateness of the rati...

Gilead Sciences, Inc.: Steady growth in core HIV and oncology products...

Our credit view of this issuer reflects its status as a global market leader in HIV therapies, against its somewhat limited revenue diversity at the product and category level.

Moody's announces completion of a periodic review of ratings of Gilead...

Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of Gilead Sciences, Inc. and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 4 January 2024 in which Moody's reassessed the appropriateness of the rat...

Adtalem Global Education Inc: 1 director

A director at Adtalem Global Education Inc sold 4,200 shares at 60.000USD and the significance rating of the trade was 50/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two y...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

Year-End Rally to Continue? The broad equity market has been on an absolute tear since we discussed in our 10/31/23 Compass how risk/reward favored buyers as key supports were being tested, including 4165 on the S&P 500, $162-$163 on the Russell 2000 (IWM), and $350 on the Nasdaq 100 (QQQ). Furthermore, we discussed in our 11/7/23 Compass our belief that this was more than just another counter-trend rally, and that it is likely the start of a significant year-end rally. We also reiterated our b...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

U.S. Dollar (DXY) and Treasury Yields Breaking Out Since early-July, and reiterated in last week's U.S. Macro Vision (9/19/23), we have expected to see 4300-4325 act as major support on the S&P 500, while also noting in our 8/29/23 Compass that we expected consolidation between 4300-4325 support and 4600 resistance until the end of September, and possibly longer. Though there is still hope that this 4300-4325 support zone holds, odds of a deeper pullback to SPX 4165-4200/the 200-day MA have inc...

Gilead Sciences, Inc.: Steady core performance, while execution of onc...

Our credit view of this issuer reflects its status as a global market leader in HIV therapies, against its somewhat limited revenue diversity at the product and category level.

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch